Patents by Inventor Justin PIERSON

Justin PIERSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240360455
    Abstract: The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and one or more C22 hydrocarbon chains conjugated to one or more internal positions on at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a skeletal muscle disorder, a cardiac muscle disorder, or an adipose tissue disorder.
    Type: Application
    Filed: April 10, 2024
    Publication date: October 31, 2024
    Inventors: Jayaprakash K. Nair, Justin Pierson, Elena Castellanos-Rizaldos, Yesseinia Anglero-Rodriguez, Karyn Schmidt, Lucas D. BonDurant, Kevin Dooley, Ivan Zlatev, Vasant R. Jadhav, Martin A. Maier, Alexander V. Kel'in, Masaaki Nakata
  • Publication number: 20230049529
    Abstract: The disclosure is directed to dual variable domain immunoglobulin double-stranded RNA conjugates that are advantageous for inhibition of target gene expression, as well as compositions suitable for therapeutic use. The dual variable domain immunoglobulin comprises a first variable domain that binds to a binding target, and a second variable domain that comprises a reactive residue, where the linker is covalently conjugated to the reactive residue. The dsRNA is linked to the linker and is capable of inhibiting the expression of the target gene by RNA interference. The disclosure also provides pharmaceutical compositions comprising these conjugate and methods of inhibiting the expression of a target gene by administering these conjugates, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: June 18, 2020
    Publication date: February 16, 2023
    Applicants: Alnylam Pharmaceuticals, Inc., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Alexander V. KEL'IN, Alex R. NANNA, Christopher RADER, Christopher THEILE, Justin PIERSON, Kevin FITZGERALD, Zhi Xiang VOO